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Background: Variants in CUBN, the gene encoding cubilin, a proximal tubular transport protein, have been
associated with albuminuria and vitamin B12 (B12) deficiency. We hypothesized that low levels of B12 would be
associated with albuminuria in a population-based cohort.
Methods: We analyzed participants from the Framingham Heart Study (n = 2965, mean age 58 years, 53% female)
who provided samples for plasma B12. Logistic regression models adjusted for covariates including homocysteine
were constructed to test the association between B12 and prevalent albuminuria (UACR ≥17 mg/g [men] and ≥25
mg/g [women]) and reduced kidney function (defined as an eGFR < 60 ml/min/1.73 m2, RKF). Because of a significant
interaction between B12 and homocysteine in the prevalent RKF model (p = 0.005), the model was stratified by the
median homocysteine levels. Logistic regression models were constructed to test the association between B12 and
incident albuminuria and RKF. The results were replicated in 4445 participants from NHANES 2003–2004.
Results: Baseline B12 levels ranged from 50-1690 pg/ml. Elevated B12 was associated with prevalent albuminuria
(OR 1.44 per 1 SD increase, 95% CI 1.10-1.87) and RKF (OR 1.83, 95% CI 1.30-2.60). However after stratifying by
median homocysteine levels, this relationship remained only in the higher homocysteine stratum. There was no
association between B12 and incident albuminuria (OR 1.17, 95% CI 0.79 – 1.73) or RKF (OR 1.45, 95% CI 0.97 – 1.88).
In the NHANES cohort, elevated B12 was associated with RKF after full covariate adjustment (OR 3.06, 95% CI 2.30-4.08).
There was no association with albuminuria.
Conclusion: In participants with high baseline homocysteine levels, increased plasma B12 was associated with RKF.
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Vitamin B12 (B12) is a water-soluble vitamin that plays
a key role in the normal function of the nervous system
and blood formation along with serving as a cofactor for
the formation of methionine from homocysteine [1].
Normally, B12 is released from dietary protein in the
stomach and binds to intrinsic factor (IF). The B12-IF
complex is absorbed in the ileum via the cubilin receptor* Correspondence: foxca@nhlbi.nih.gov
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unless otherwise stated.[1]. Defects in cubilin, a proximal tubular membrane
protein, have been associated with both megaloblastic
anemia and tubular proteinuria [1-4]. Cubilin also acts
to reabsorb the majority of filtered albumin from the
urine and recently, genome-wide association studies
have identified SNPs in CUBN in association with albu-
minuria [5] and B12 levels [6,7].
B12 deficiency is associated with anemia and neuro-
logical disorders. Through its central role in homocysteine
metabolism, low B12 levels have been associated with
higher serum homocysteine, a risk factor for cardiovascu-
lar disease [3]. However, in CKD homocysteine levels
increase as GFR declines, independent of B12 levels [8].ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cessing of B12 and albumin in the gut and the kidney.
The purpose of this study was to evaluate the association
between B12 levels, albuminuria and reduced kidney
function (RKF). We hypothesized that lower levels of
B12 would be associated with an increased risk of albu-
minuria and RKF and that this association would be
modified by homocysteine. To study this, we examined
these associations in participants from the Framingham
Heart Study. We further replicated our results in partici-
pants from the National Health and Nutrition Examin-
ation Survey (NHANES) 2003–2004. To account for the
independent relationships of homocysteine with CKD
and serum B12 levels, we further adjusted for baseline
homocysteine levels.Methods
Study samples
Framingham Heart Study (FHS) participants were drawn
from the Offspring Study cohort [9]. Participants in the
Offspring cohort are the children and spouses of the ori-
ginal Framingham cohort who underwent assessments in
4–8 year cycles including a physical examination, blood
and urine biochemistries, assessment of cardiovascular
risk factors and a physician interview. To be included in
this study, participants were required to have attended the
Offspring sixth examination cycle (1995–1998), provided
a serum sample for B12 and provided a specimens to
measure the urinary albumin/creatinine ratio (UACR)
[albuminuria analysis] and serum creatinine [RKF ana-
lysis]. In total 3,532 participants attended the sixth
examination cycle. Of these, 2965 participants provided
samples for UACR and B12 measurement and were
included in the albuminuria analysis. For the RKF analysis,
3,464 participants provided samples for serum creatinine
and B12 measurements. Participants missing covariates
(n = 13) were excluded leaving 3,451 participants in
the final RKF analysis. All participants provided writ-
ten informed consent. The study was approved by the
Institutional Review Board at Boston University.
NHANES 2003–2004 was a stratified, multistage prob-
ability survey designed to select a representative sample
of the civilian non-institutionalized US population. This
examination cycle was chosen as it was the only one
where both B12 and homocysteine were available. After
excluding participants younger than 18 years of age and
those participants lacking a measurement of B12, urinary
albumin and creatinine or serum creatinine, 4,445 par-
ticipants were included in the analysis of B12 and RKF
and 4,395 participants were included in the analysis of B12
and albuminuria. The protocol for NHANES 2003–2004
was approved by the National Center for Health Statis-
tics of the Center for Disease Control and PreventionInstitutional Review Board. All participants gave informed
consent.
Measurement of B12
FHS participants provided fasting morning plasma samples
that were stored at −80°C until processing. B12 was mea-
sured using a chemoluminescence assay (Immulite 1000
Immunoassay, Siemens). The coefficient of variation of the
assay was 9.3%.
In NHANES 2003–2004, levels of B12 were measured
using Bio-Rad Laboratories Quantaphase II Folate/B12
radioassay kit.
Albuminuria
In FHS participants, UACR was measured on spot urine
samples at the Offspring sixth and eighth examination
cycles. Urine samples were collected and stored at −20°C.
The urinary albumin concentration was assayed using
immunoturbidimetry (Tina Quant Albumin Assay, Roche
Diagnostics). Urinary creatine was measured using the
modified Jaffé method (Colorimetric Assay, Roche Diagnos-
tics). We defined albuminuria defined as a UACR ≥17 mg/g
in men and ≥25 mg/g in women at exam 6. Incident albu-
minuria was defined as albuminuria at exam 8 in partici-
pants without albuminuria at exam 6.
In NHANES 2003–2004, urinary albumin was measured
by solid phase fluorescence immunoassay and creatinine
was measured by the modified kinetic Jaffe method on
random spot urine samples.
Reduced kidney function
Serum creatinine levels were assayed using the modi-
fied Jaffé method in both FHS and NHANES. We de-
fined RKF as an estimated glomerular filtration rate
(eGFR) <60 ml/min/1.73 m2 using the CKD-EPI equa-
tion [10]. Incident RKF was defined as the development
of RKF by the Offspring eighth examination cycle
(2005–2008) in FHS participants.
Covariate assessment
Covariates were obtained from FHS participants at the
baseline examination. Systolic and diastolic blood pres-
sures were recorded as the average of two physician-
performed measurements. Hypertension was defined as a
systolic blood pressure of ≥140 mmHg, a diastolic blood
pressure of ≥90 mmHg or the use of antihypertensive
medications. Serum glucose and high density lipoprotein
cholesterol (HDLc) were measured on fasting blood sam-
ples. Diabetes mellitus was defined as a fasting blood sugar
of ≥126 mg/dl or treatment with a hypoglycemic agent.
Dipstick proteinuria was defined as the presence of trace
or more proteinuria on dipstick (Ames Labstix, Elkhart,
Indiana). Participants were considered current smokers if
they had smoked ≥1 cigarette per day over during the
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the participant’s weight in kilograms divided by their
height in meters squared. Plasma homocysteine was mea-
sured by high-performance liquid chromatography with
fluorimetric detection. The coefficient of variation of the
assay was 9%.
In NHANES 2003–2004, questionnaires were used to
assess participants’ age, sex, smoking status, prior diag-
nosis of hypertension and diabetes and use of antihyper-
tensive and hypoglycemic medications. Blood pressure
was measured three times by a trained physician follow-
ing a standardized protocol. Hypertension was defined
as systolic blood pressure ≥ 140 mm Hg, diastolic blood
pressure ≥ 90 mm Hg, or use of antihypertensive medi-
cation. Serum glucose was measured using a Beckman Syn-
chron LX20 analyzer and diabetes was defined as a fasting
glucose ≥ 126 mg/dL, non-fasting glucose ≥ 200 mg/dL, or
a self-reported history of diabetes with concurrent use of
hypoglycemic medication. HDLc was measured using the
Hitachi 704 Analyzer. Plasma homocysteine was measured
using a fluorescence polarization immunoassay (Abbott
Diagnostics, Lake Forest, IL).Statistical analysis
We grouped the baseline characteristics of the FHS partic-
ipants by quartile of B12 level. We calculated the statis-
tical significance of differences using χ2 test for categorical
variables and ANOVA for continuous variables. Because
the B12, homocysteine and UACR were not normally dis-
tributed, these were log-transformed for the purpose of
the analysis. The association between B12 and eGFR, sys-
tolic blood pressure, HDLc, BMI, UACR and homocyst-
eine was estimated using Pearson correlation coefficients
adjusted for age and sex.
We constructed a logistic regression model, adjusted
for age and sex, to test the association between B12 and
albuminuria. Log-transformed B12 was treated as a con-
tinuous variable and odds ratios (OR) were calculated
per 1 standard deviation increase. We further adjusted
the model for systolic blood pressure, HDLc, smoking,
hypertension treatment and the presence of diabetes. Be-
cause elevated homocysteine is associated with CKD and
albuminuria and homocysteine levels are known to be
altered by B12 [3], the final model included an adjustment
for baseline homocysteine levels. We then repeated these
analyses after stratifying participants by the median base-
line homocysteine levels.
We tested the relationship between B12 and RKF at the
baseline examination using a logistic regression model
adjusted for age, sex, diabetes, hypertension and dipstick
proteinuria. The model was further adjusted for baseline
homocysteine levels. Because homocysteine significantly
modified the relationship between B12 and RKF, werepeated the analysis after stratifying by the median base-
line homocysteine levels.
We used a logistic regression model to estimate the
association between B12 and incident albuminuria in FHS
participants, defined as UACR ≥17 mg/g in men and
≥25 mg/g in women at Offspring examination cycle 8
[2005–2008]. Participants with albuminuria at the baseline
examination were excluded. The incident albuminuria
model was adjusted for age, sex, systolic blood pressure,
HDLc, smoking status, hypertension treatment and the
presence of diabetes. We then further adjusted the model
for baseline homocysteine levels. Because there was no
interaction between B12 and homocysteine in the incident
analyses, no stratified analysis was done.
We tested the association between B12 and incident
RKF using a logistic regression model. The multivariable
adjusted model included age, sex, baseline eGFR, dia-
betes, hypertension and dipstick proteinuria. This model
was again adjusted for baseline homocysteine levels.
Statistical analyses were performed using SAS, version
9.2 (Cary, North Carolina). A two-tailed p-value of <0.05
was considered significant.
To replicate our findings, we constructed identical
logistic regression models to test the cross-sectional
association between B12, albuminuria and RKF in par-
ticipants from NHANES 2003–2004. The models were
adjusted and stratified as described above for FHS.
Analyses for NHANES 2003–2004 were performed
using SUDAAN 10.1 (Research Triangle Institute, Re-
search Triangle Park, NC) accounting for this study’s
complex sampling design, including unequal probabil-
ities of selection, over-sampling, and non-response.
Sampling weights were applied for all NHANES 2003–2004
analyses to produce estimates that are representative of
the national U.S population.Results
Baseline characteristics
In total, 2,965 FHS participants were included in the
study. Baseline B12 ranged from 50–1690 pg/ml. In
total, 135 participants had B12 levels below 200 pg/ml.
The characteristics of the participants, stratified by
quartile of vitamin B12, are shown in Table 1. There
was no difference in baseline eGFR, UACR or the
prevalence of albuminuria across vitamin B12 quartiles.
There was an inverse relationship between vitamin B12
and homocysteine levels across quartiles (p < 0.0001 for
trend).
Plasma B12 was weakly correlated with HDLc (r = 0.06,
p = 0.002) and BMI (r = −0.08, p < 0.001). There was an
expected negative correlation with plasma homocysteine
levels (r = −0.29, p < 0.001). There was no correlation
between B12 levels and UACR or eGFR.
Table 1 Baseline characteristics of the Framingham Offspring Study participants stratified by quartiles of serum B12
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Characteristic Mean/n/median Mean/n/median Mean/n/median Mean/n/median p-value*
N 741 741 742 741
B12, mean, pg/ml (SD) 243 (47) 348 (25) 444 (32) 648 (153)
B12, range, pg/ml (IQR) 50-306 307-393 394-502 503-1690
Age, years (SD) 58.7 (10.0) 58.4 (9.9) 58.5 (9.4) 58.7 (9.6) 0.92
Sex, n (%women) 382 (51.6) 359 (48.4) 379 (51.1) 458 (61.8) 0.16
Diabetes, n, (%) 64 (8.6) 63 (8.5) 81(10.9) 73 (9.8) 0.07
Systolic BP, mmHg (SD) 128.1 (18.5) 128.8 (19.5) 128.8 (18.4) 128.1 (19.1) 0.81
Diastolic BP, mmHg (SD) 75.6 (9.3) 75.7 (9.9) 75.7 (9.3) 78.1 (9.3) 0.81
Hypertension Treatment, n (%) 207 (28.0) 207 (27.9) 206 (27.7) 199 (26.9) 0.98
Body Mass Index, kg/m2 (SD) 28.3 (5.0) 28.0 (4.9) 28.2 (5.7) 27.2 (5.0) <0.001
HDLc, mg/dl (SD) 50.2 (15.4) 50.0 (16.1) 51.1 (16.1) 52.6 (16.9) 0.17
Current Smoker, n (%) 116 (15.7) 119 (16.1) 112 (15.1) 103 (13.9) 0.51
eGFR, ml/min/1.73 m2 (SD) 85.1 (18.2) 85.3 (19.1) 84.6 (18.6) 84.9 (19.5) 0.68
RKF, n (%) 87 (10.1) 72 (8.4) 78 (9.0) 82 (9.5) 0.91
UACR, mg/g (IQR) 6.1 (2.7-13.5) 5.9 (2.5-15.6) 6.1 (2.9-14.9) 7.6 (3.2-17.4) 0.49
Microalbuminuria, n (%) 115 (15.5) 133 (17.9) 131 (17.7) 144 (19.4) 0.1
Homocysteine, μmol/L (SD) 11.2 (5.1) 9.9 (3.5) 9.2 (2.8) 8.6 (3.0) <0.001
*Test for significance of linear trend adjusted for age and sex.
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In the cross-sectional age- and sex-adjusted and multi-
variable-adjusted models, there was no association between
levels of B12 and prevalent albuminuria (Table 2) in FHS
participants. However, after adjustment for homocysteine
levels, higher B12 levels were associated with an in-
creased risk of albuminuria (OR 1.44 per 1 SD increase,
95% CI 1.10 – 1.87). There was no interaction between B12Table 2 The cross-sectional association between B12 (OR per
and RKF at Offspring Examination 6
Model 1
n Events (%) OR CI p-
Entire Cohort
Albuminuria 2965 523 (17.6) 1.25 0.98-1.60
RKF 3451 319 (9.2) 0.99 0.72-1.35
Stratified analysis: Albuminuria*
Homocysteine < median 1511 228 (15.1) 1.28 0.87-1.88
Homocysteine ≥median 1454 295 (20.3)† 1.45 1.03-2.03
Stratified analysis: RKF*
Homocysteine < median 1722 70 (4.1) 0.90 0.47-1.75
Homocysteine ≥median 1729 249 (14.4)† 1.62 1.10-2.37
Model 1: Age- and sex- adjusted.
Model 2: Multivariable-adjusted: Albuminuria - systolic blood pressure, HDLc, smokin
RKF: diabetes, hypertension and dipstick proteinuria.
Model 3: Multivariable-adjusted + baseline log homocysteine.
*Stratified by the median homocysteine levels (9.08 μmol/L).
†p-value <0.001 for comparison.and homocysteine (pinteraction = 0.63). When the participants
were stratified by homocysteine levels, there was no associ-
ation between B12 and albuminuria after full covariate ad-
justment (OR 1.27, 95% CI 0.85 – 1.90) in participants with
homocysteine levels < 9.08 μmol/L. However, in partici-
pants with homocysteine above the median, higher B12
levels were associated with albuminuria (OR 1.57, 95% CI
1.10 – 2.26).1SD increase log Vitamin B12) and prevalent albuminuria
Model 2 Model 3
value OR CI p-value OR CI p-value
0.07 1.25 0.97-1.61 0.08 1.44 1.10-1.87 0.008
0.94 0.98 0.72-1.35 0.92 1.83 1.30-2.59 <0.001
0.21 1.29 0.87-1.91 0.21 1.27 0.85-1.90 0.24
0.03 1.41 0.99-2.01 0.06 1.57 1.10-2.26 0.01
0.76 0.92 0.47-1.78 0.80 1.22 0.62-2.41 0.56
0.01 1.57 1.06-2.31 0.02 2.17 1.44-3.26 <0.001
g status, hypertension treatment and diabetes.
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In cross-sectional age- and sex-adjusted models and the
multivariable model, there was no association between
B12 and RKF (Table 2). After adjusting for homocysteine,
there was an association between B12 and RKF (OR 1.83,
95% CI 1.30 – 2.60). The association between B12 and
RKF differed by level of homocysteine (pinteraction = 0.005).
After stratifying by median homocysteine (9.08 μmol/L),
the relationship between B12 and RKF remained robust in
participants with homocysteine ≥ 9.08 μmol/L (OR 2.17,
95% CI 1.44 – 3.26). However, at lower levels of homocyst-
eine, there was no association between B12 and RKF (OR
1.22, 95% CI 0.62 – 2.41).
B12 in association with incident albuminuria
Of those patients (n = 1931) who returned for the
follow-up examination and provided samples for UACR,
214 (11.1%) developed albuminuria. There was no asso-
ciation between B12 levels and incident albuminuria
after multivariable adjustment (OR 0.96, 95% CI 0.66-
1.39, Table 3) or after further adjustment for baseline
homocysteine levels (OR 1.17, 95% CI 0.79 – 1.73,
Table 3). There was no interaction between B12 and
homocysteine (p = 0.11).
B12 in association with incident RKF
For the analysis of the association between B12 and inci-
dent RKF, 2,382 participants were included (Table 3). In
total, 237 participants had an RKF at the follow-up
examination (11.0%). There was no association between
B12 and incident RKF after multivariable adjustment ei-
ther before (OR 0.99, 95% CI 0.69-1.53) or after baseline
homocysteine adjustment (OR 1.32, 95% CI 0.87 – 2.02).
Finally, there was no interaction between B12 and
homocysteine (p = 0.06).
External replication in NHANES 2003–2004 participants
In contrast to the results in FHS participants, in the
NHANES cohort, there was no association between B12
and albuminuria in the unadjusted and multivariable-
adjusted analysis or after adjustment for homocysteine
levels (Table 4). No association was present between
vitamin B12 and albuminuria for NHANES participantsTable 3 The association between B12 and incident albuminur
Model 1
n Events (%) OR CI p-value
Albuminuria 1931 214 (11.1) 0.96 0.67-1.38 0.84
RKF 2145 237 (11.0) 1.00 0.72-1.53 0.81
Model 1: Age- and sex- adjusted.
Model 2: Multivariable-adjusted: Albuminuria - systolic blood pressure, HDLc, smokin
RKF: diabetes, hypertension, baseline eGFR and dipstick proteinuria.
Model 3: Multivariable-adjusted + baseline lnhomocysteine.
OR are presented per 1SD increase log Vitamin B12.with homocysteine levels above or below the median
(8.34 μmol/L).
Similar to the FHS cohort, there was no cross-
sectional association between vitamin B12 and RKF in
the age- and sex-adjusted and multivariable-adjusted
models. After further adjustment for homocysteine
levels, there was an association between B12 and RKF
(OR 3.06, 95% CI 2.30-4.08, Table 4). After stratifying by
the median homocysteine level, there was an association
between B12 and RKF in the higher homocysteine
stratum (OR 3.46, 95% CI 2.64-4.53) but not in the
lower homocysteine stratum (OR 0.62 95% CI 0.14-
2.76). There was a significant interaction between B12
and homocysteine (pinteraction <0.001).
Discussion
The findings of this study are fourfold. First, we found
that B12 was not associated with albuminuria or RKF in
the univariate or multivariable-adjusted model. However,
elevated levels of B12 were associated cross-sectionally
with a higher odds of albuminuria after adjusting for the
plasma homocysteine concentration. After further strati-
fication by the median homocysteine concentration, the
association between B12 and albuminuria remained only
in the higher homocysteine group. However, this result
did not replicate in the NHANES cohort.
Third, elevated B12 levels were associated cross-
sectionally with a higher odds of RKF after adjusting for
the plasma homocysteine concentration. The association
between B12 and RKF remained only in the higher
homocysteine group after stratification by the median
homocysteine level. This result was confirmed in partici-
pants from the NHANES cohort. Finally, there was no
association between B12 levels and incident albuminuria
and RKF.
In the context of the current literature
B12 levels are a function of dietary intake and deficien-
cies result from reduced intake or decreased absorption
in the ileum. Defects in gut and proximal tubular trans-
port proteins have been associated with albuminuria and
B12 deficiency [1,4]. B12 deficiency has been well de-
scribed but elevations in B12 levels have not been as well
studied. There is no upper recommended daily limit foria and incident RKF in the Framingham Heart Study
Model 2 Model 3
OR CI p-value OR CI p-value
0.96 0.66-1.39 0.81 1.17 0.79-1.73 0.44
0.99 0.69-1.53 0.90 1.32 0.87-2.02 0.19
g status, hypertension treatment and diabetes.
Table 4 The cross-sectional association between B12 (OR per 1SD increase lnB12) and prevalent albuminuria and RKF
in the NHANES 2003–2004 study
Model 1 Model 2 Model 3
n Events (%)1 OR CI p-value OR CI p-value OR CI p-value
Entire cohort
Albuminuria 4395 764 (13.3) 1.05 0.87-1.27 0.56 1.13 0.88-1.45 0.26 1.16 0.89-1.50 0.26
RKF 4445 489 (7.0) 1.13 0.85-1.51 0.37 1.17 0.85-1.61 0.32 3.06 2.30-4.08 <0.001
Stratified analysis: Albuminuria2
Homocysteine < median 2196 277 (11.5) 1.14 0.86-1.51 0.32 1.27 0.88-1.83 0.18 1.24 0.84-1.83 0.26
Homocysteine ≥median 2197 487 (15.1) 1.05 0.80-1.36 0.72 1.05 0.79-1.40 0.26 1.18 0.88-1.59 0.26
Stratified analysis: RKF2
Homocysteine < median 2222 18 (0.7) 0.64 0.15-2.74 0.52 0.63 0.14-2.85 0.52 0.62 0.14-2.76 0.51
Homocysteine ≥median 2223 471 (13.3) 1.56 1.16-2.09 0.01 1.59 1.16-2.17 0.01 3.46 2.64-4.53 <0.001
Model 1: Age- and sex- adjusted.
Model 2: Multivariable-adjusted: Albuminuria - systolic blood pressure, HDLc, smoking status, hypertension treatment and diabetes.
RKF: diabetes, hypertension and dipstick proteinuria.
Model 3: Multivariable-adjusted + lnhomocysteine.
1Percentages are weighted to reflect the US population and take into account the multi-stage complex sampling design used to enroll NHANES participants.
2Stratified by the median homocysteine levels (8.34 μmol/L).
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However, elevations in B12 have been noted in associ-
ation with a variety of conditions including liver disease,
malignancies, and inflammatory disorders [12]. The stron-
gest predictor of elevated B12 levels in hospitalized pa-
tients is CKD [13,14]. The mechanism for this increase is
unclear. Under normal circumstances, although B12 is fil-
tered at the glomerulus, excretion in the urine is minimal
due to reabsorption in the proximal tubule [3]. As such,
high B12 levels found in the setting of CKD should not be
related to decreased clearance. However, in the setting of
exogenous administration of B12, the kidneys are an im-
portant route for excretion as the reabsorptive mechanism
is saturable. Thus, the administration of supraphysiologic
doses of B12 to individuals with CKD could lead to an
elevated in the serum concentration.
Typically there is an inverse relationship between levels
of homocysteine and B12. However, this relationship is al-
tered in patients with CKD. Although B12 supplementa-
tion reduces homocysteine levels in patients with CKD, it
is less effective than in patients with normal renal function
[5]. In patients on hemodialysis, continuous replacement
of B12 is required to maintain lower homocysteine levels
despite normal plasma B12 values [15].
In this study, as expected, we found that B12 was in-
versely associated with homocysteine. B12 levels were
not associated with RKF prior to adjustment for homo-
cysteine or in individuals with homocysteine levels below
the median. This suggests that elevated B12 alone is not
associated with an increased risk for RKF. However, in
patients with elevated homocysteine levels, higher vita-
min B12 concentrations were associated with an in-
creased prevalence of RKF. The combination of elevated
homocysteine along with increased B12 suggests thepossibility of a resistance to the usual effects of B12 in
these individuals.
Potential mechanisms
B12 in the blood is primarily protein-bound. Approxi-
mately 20% of circulating B12 is bound to holotransco-
balamin (TC2) with the remainder to haptocorrin [16].
TC2-bound B12 is the biologically active form as B12
bound to haptocorrin cannot be taken up into cells [16].
A congenital form of megaloblastic anemia has been de-
scribed in infants lacking TC2 despite normal total B12
levels [17]. The kidney plays an important role in TC2
metabolism. TC2 is filtered at the glomerulus and is
reabsorbed in the proximal tubule by megalin. B12 is
then returned to the blood bound to newly synthesized
TC2 [18]. Thus, defects in protein reabsorption in the
proximal tubule could lead to a loss of biologically active
TC2 in the urine.
Increased TC2 and haptocorrin levels have been noted
in patients with CKD [13]. Despite this, there is decreased
uptake of TC2 into cells [18,19]. This can lead to a para-
doxical increase in cellular homocysteine levels despite
normal total B12. Thus, a functional B12 deficiency can
occur in patients with CKD in the setting of increased
TC2 losses in the urine, decreased TC2 absorption in the
proximal tubule and decreased cellular uptake of TC2.
Another important consideration is the possibility that
elevated B12 levels and B12 supplementation may be
harmful in individuals with CKD. Cyanide metabolism is
abnormal in individuals with CKD due to decreased
clearance [20]. Cyanocobalamin, the most commonly
used form of B12 replacement is metabolized to active
methylcobalamin releasing small amounts of cyanide.
Under normal circumstances, methylcobalamin acts as a
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conversion to cyanocobalamin. However, in patients with
CKD the reduced cyanide clearance prevents conversion
of cyanocobalamin to the active form and therefore sup-
plementation in this form is less effective at reducing
homocysteine levels [21].
In fact, a recent randomized trial of cyanocobalamin
administration found more rapid GFR decline and car-
diovascular morbidity in the treatment arm [22]. It was
suggested that this may be related to increased synthesis
of assymetric dimethylarginine which is known to inhibit
nitric oxide. However, the data above suggest that in fact
this finding may result from the use of cyanocobalamin
rather than methylcobalamin in this population and that
methylcobalamin should be preferred in individuals with
CKD. Unfortunately, as we do not have data on vitamin
supplementation, this is speculative and would warrant
further investigation.
Implications
There are a number of implications to this study. First,
although previous studies have demonstrated that total
B12 levels may not accurately reflect B12 status in pa-
tients with CKD, our study shows that this is true even
in individuals with moderate declines in renal function.
This, however, is complicated by the general increase in
homocysteine seen in patients with CKD that is unre-
lated to B12 levels [12]. The appropriate range of B12
levels in CKD remains to be defined adequately. Down-
stream metabolites such as methylmalonic acid and homo-
cysteine may more accurately reflect functional B12 status
in patients with CKD. Similarly, whether monitoring TC2
levels rather than total B12 is more appropriate in patients
with CKD is unclear and warrants further study. The
means of B12 supplementation chosen may be import-
ant in individuals with CKD.
Finally, although B12 was associated cross-sectionally
with RKF, there was no association with incident RKF or
albuminuria. This suggests that the altered metabolism
of B12 is present only in individuals with established
RKF and that elevated levels are not a risk factor for fu-
ture CKD. This is supported by the fact that B12 supple-
mentation was found to be harmful only in individuals
with GFR < 50 ml/min/1.73 m2 [22] and had no effects
(positive or negative) in subjects with normal renal func-
tion. All of the patients in the incident RKF analysis had
an eGFR >60 ml/min/1.73 m2 at the time that B12 and
homocysteine were measured.
Strengths and limitations
The well-characterized Framingham Heart Study and
well-defined cardiovascular risk factors are an important
strength of this study. We performed independent repli-
cation of our findings in the NHANES study. However,there are a number of limitations that should be stated.
B12 levels are related to dietary intake and the use of
supplements which were not recorded [23,24]. Similarly,
the influence of folate supplementation on homocysteine
levels is substantial and may introduce some bias by al-
tering the relationship between B12 and homocysteine.
Albuminuria and RKF were defined on the basis of single
measurements which might lead to some misclassification.
Our findings are observational and causality cannot be
inferred.
Conclusion
In subjects with high homocysteine levels, increased
plasma B12 was associated with prevalent RKF.
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